EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Treatment Patterns and Healthcare Resource Utilization in Tardive Dyskinesia: Claims Analysis of Individuals Treated with Benztropine or a VMAT2 Inhibitor

Craig Chepke, Handing Xie, Sagnik Chatterjee, Pooja Gandhi, Amy Yang

Journal of Health Economics and Outcomes Research · 13.11.2026 · 13 (2)

DOI: 10.36469/001c.169275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 13.11.2026. Verfasst von Craig Chepke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Excel Psychiatric Associates, Huntersville, NC, USA. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with the use of dopamine receptor antagonists. Despite vesicular monoamine transporter type 2 (VMAT2) inhibitors being recommended as first-line treatment, benztropine is sometimes prescribed off-label and may aggravate TD symptoms.

Objective

To compare US healthcare resource utilization (HCRU) between benztropine-treated and nontreated and between benztropine-treated and VMAT2 inhibitor–treated individuals with TD.

Methods

Retrospective claims analyses included individuals with TD with ≥1 year of continuous insurance coverage before and after treatment initiation (index date). Part 1 (MarketScan® database [July 2012–Sept. 2021]) included adults with first TD diagnosis from July 2013 to September 2020. Individuals with benztropine initiated on/after first TD diagnosis were matched exactly by age, sex, and the Quan adaptation of the Charlson Comorbidity Index to nontreated individuals. Part 2 (MarketScan® [Jan. 2016–Sept. 2023]; Medicaid [Jan. 2018–Dec. 2022]) included adults with TD diagnosis (Jan. 2017–Sept. 2022) ≤1 year before benztropine or VMAT2 inhibitor initiation. VMAT2 inhibitor–treated and benztropine-treated cohorts underwent 1:1 propensity score matching. All-cause HCRU was compared between matched cohorts.

Results

In part 1, 92 benztropine-treated individuals with TD were matched to 92 nontreated individuals with TD (mean age, 47.7 years; 77.2% female). Post-index, mean (SD) annual number of emergency department visits was significantly higher for benztropine-treated individuals than nontreated individuals (1.0 [1.8] vs 0.5 [1.0]; P = .0232). In part 2, post-index, significantly higher proportions of individuals in the benztropine-treated cohort (n = 272) vs the matched VMAT2 inhibitor–treated cohort (n = 272) had ≥1 inpatient visit (36.8% vs 22.1%; P < .001). Mean (SD) numbers of inpatient (0.9 [2.2] vs 0.5 [1.2]; P = .004) and emergency department visits (2.6 [6.0] vs 1.6 [4.0]; P = .024) were higher in the benztropine-treated vs VMAT2 inhibitor–treated cohorts, respectively.

Conclusion

Treatment of TD with benztropine was associated with higher all-cause HCRU than no treatment or VMAT2 inhibitor treatment.

Schlagwörter

Stichwörter der Autor:innen

VMAT2 inhibitoranticholinergicsbenztropinehealthcare resource utilizationmovement disorderstardive dyskinesia

Autor:innen und Institutionen

  • Excel Psychiatric Associates, Huntersville, NC, USA.
  • Atrium Health, Charlotte, North Carolina, USA.
  • Teva Branded Pharmaceutical Products R&D LLC, West Chester, Pennsylvania, USA.
  • KMK Consulting, Inc., Morris Plains, New Jersey, USA.
  • Teva Branded Pharmaceutical Products R&D LLC, Parsippany, New Jersey, USA.

Zitieren

APA

Chepke, C., Xie, H., Chatterjee, S., Gandhi, P., & Yang, A. (2026). Real-World Treatment Patterns and Healthcare Resource Utilization in Tardive Dyskinesia: Claims Analysis of Individuals Treated with Benztropine or a VMAT2 Inhibitor. Journal of Health Economics and Outcomes Research, 13(2). https://doi.org/10.36469/001c.169275

Vancouver

Chepke C, Xie H, Chatterjee S, Gandhi P, Yang A. Real-World Treatment Patterns and Healthcare Resource Utilization in Tardive Dyskinesia: Claims Analysis of Individuals Treated with Benztropine or a VMAT2 Inhibitor. Journal of Health Economics and Outcomes Research. 2026;13(2). doi:10.36469/001c.169275

BibTeX
@article{Chepke2026,
  author = {Chepke, Craig and Xie, Handing and Chatterjee, Sagnik and Gandhi, Pooja and Yang, Amy},
  title = {Real-World Treatment Patterns and Healthcare Resource Utilization in Tardive Dyskinesia: Claims Analysis of Individuals Treated with Benztropine or a VMAT2 Inhibitor},
  journal = {Journal of Health Economics and Outcomes Research},
  year = {2026},
  volume = {13},
  number = {2},
  doi = {10.36469/001c.169275}
}
Kostenlos starten →